74. 下垂体性PRL分泌亢進症
[臨床試験数:18,薬物数:33(DrugBank:10),標的遺伝子数:16,標的パスウェイ数:63

Searched query = "Prolactin secreting pituitary adenoma", "Pituitary PRL secretion hyperthyroidism", "Prolactinoma", "Prolactin secreting adenoma"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04107480
(ClinicalTrials.gov)
June 21, 201927/8/2019PRolaCT - Three Prolactinoma RCTsPRolaCT - Three Multicenter Prolactinoma Randomized Clinical TrialsProlactinoma;Prolactin-Producing Pituitary TumorProcedure: Endoscopic trans-sphenoidal adenoma resection;Drug: Dopamine AgonistsLeiden University Medical CenterNULLRecruiting18 YearsN/AAll880Phase 4Netherlands
2NCT03717454
(ClinicalTrials.gov)
December 1, 201814/10/2018Dopamine D2 Receptors(D2R) Imaging in ProlactinomasThe Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of of Prolactinomas.ProlactinomaOther: Surgery;Drug: Drug treatmentZhebao WuXinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General HospitalNot yet recruiting18 Years65 YearsAll50N/ANULL
3NCT03400865
(ClinicalTrials.gov)
October 25, 20188/1/2018Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant ProlactinomasThe Effect of Combined Treatment of Cabergoline With Hydroxychloroquine/Chloroquine for Resistant ProlactinomasResistance, Disease;ProlactinomaDrug: HCQ/CQ and CAB combined treatmentZhebao WuXinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General HospitalNot yet recruiting18 Years70 YearsAll30N/AChina
4NCT03457389
(ClinicalTrials.gov)
February 22, 201823/1/2018Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With ProlactinomaComparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma: A Prospective, Randomized, Open Label, Active-controlled, Clinical TrialPituitary Adenoma;Prolactinoma;Pituitary Tumor;Recurrence TumorDrug: CabergolineSeoul National University HospitalNULLRecruiting19 YearsN/AAll68N/AKorea, Republic of
5NCT03038308
(ClinicalTrials.gov)
September 16, 201630/1/2017Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist RopiniroleTreatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and TolerabilityHyperprolactinemia;ProlactinomaDrug: RopiniroleColumbia UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruiting18 Years70 YearsAll23Phase 1;Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03353025
(ClinicalTrials.gov)
January 1, 201620/2/2017Study on Therapy of Non-invasive ProlactinomaProspective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive ProlactinomaProlactinomaProcedure: transsphenoidal surgery treatment;Drug: dopamine agonist treatmentFirst Affiliated Hospital, Sun Yat-Sen UniversityNULLRecruiting18 Years60 YearsAll394N/AChina
7ChiCTR-ONC-12002194
2012-05-012012-05-22Artery Endothelium Function, Carotid Artery Intima-Media Thickness and Cardiac Mass and Function after Long-Term Control of HyperprolactimiaArtery Endothelium Function, Carotid Artery Intima-Media Thickness and Cardiac Mass and Function after Long-Term Control of Hyperprolactimia prolactinomapatients with prolactinoma:treatment with bromocriptine ;First affiliated hospital of Sun Yat-sen UniversityNULLCompleted1355Bothpatients with prolactinoma:40;NULL
8NCT01344291
(ClinicalTrials.gov)
July 201118/4/2011Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma PatientsHyperprolactinomaDrug: CurcuminMashhad University of Medical SciencesNULLRecruiting20 Years45 YearsFemale30Phase 1Iran, Islamic Republic of
9NCT01620138
(ClinicalTrials.gov)
March 201018/9/2011Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant ProlactinomasSomatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine AgonistNon-functioning Pituitary Adenomas;ProlactinomasDrug: Pasireotide;Drug: cabergolineUniversidade Federal do Rio de JaneiroNULLCompleted18 YearsN/AAll21Phase 2;Phase 3Brazil
10NCT01088763
(ClinicalTrials.gov)
March 201016/3/2010Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaA PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIAChildhood Atypical Teratoid/Rhabdoid Tumor;Childhood Central Nervous System Choriocarcinoma;Childhood Central Nervous System Germinoma;Childhood Central Nervous System Mixed Germ Cell Tumor;Childhood Central Nervous System Teratoma;Childhood Central Nervous System Yolk Sac Tumor;Childhood Choroid Plexus Tumor;Childhood Craniopharyngioma;Childhood Ependymoblastoma;Childhood Grade I Meningioma;Childhood Grade II Meningioma;Childhood Grade III Meningioma;Childhood Infratentorial Ependymoma;Childhood Medulloepithelioma;Childhood Mixed Glioma;Childhood Oligodendroglioma;Childhood Supratentorial Ependymoma;Gonadotroph Adenoma;Pituitary Basophilic Adenoma;Pituitary Chromophobe Adenoma;Pituitary Eosinophilic Adenoma;Prolactin Secreting Adenoma;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Anaplastic Large Cell Lymphoma;Recurrent Childhood Brain Stem Glioma;Recurrent Childhood Central Nervous System Embryonal Tumor;Recurrent Childhood Cerebellar Astrocytoma;Recurrent Childhood Cerebral Astrocytoma;Recurrent Childhood Ependymoma;Recurrent Childhood Grade III Lymphomatoid Granulomatosis;Recurrent Childhood Large Cell Lymphoma;Recurrent Childhood Lymphoblastic Lymphoma;Recurrent Childhood Medulloblastoma;Recurrent Childhood Pineoblastoma;Recurrent Childhood Small Noncleaved Cell Lymphoma;Recurrent Childhood Spinal Cord Neoplasm;Recurrent Childhood Subependymal Giant Cell Astrocytoma;Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;Recurrent Childhood Visual Pathway and Hypothalamic Glioma;Recurrent Childhood Visual Pathway Glioma;Recurrent Pituitary Tumor;Recurrent/Refractory Childhood Hodgkin Lymphoma;T-cell Childhood Acute Lymphoblastic Leukemia;T-cell Large Granular Lymphocyte Leukemia;TSH Secreting Adenoma;Unspecified Childhood Solid Tumor, Protocol SpecificDrug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;Other: diagnostic laboratory biomarker analysis;Other: pharmacological study;Drug: dexamethasoneNational Cancer Institute (NCI)NULLTerminated1 Year21 YearsBoth129Phase 1United States;Canada
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2008-007348-32-IT
(EUCTR)
07/09/200907/08/2009An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NDAn open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - ND 1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)3. Ectopic ACTH-secreting (EAS) tumors4. Nelsons syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10051747
Product Name: PASIREOTIDE
Product Code: SOM230
INN or Proposed INN: PASIREOTIDE
Product Name: PASIREOTIDE
Product Code: SOM230
INN or Proposed INN: PASIREOTIDE
Product Name: PASIREOTIDE
Product Code: SOM230
INN or Proposed INN: PASIREOTIDE
NOVARTIS FARMANULLNot RecruitingFemale: yes
Male: yes
70France;Spain;Germany;Italy
12EUCTR2008-007348-32-DE
(EUCTR)
12/08/200930/06/2009An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NAAn open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NA The following tumors are included:1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)3. Ectopic ACTH-secreting (EAS) tumors4. Nelson's syndrome
MedDRA version: 14.1;Level: LLT;Classification code 10062476;Term: Neuroendocrine tumor;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Product Name: pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Product Name: pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Product Name: pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
120Phase 2United States;Spain;Russian Federation;Colombia;Italy;France;Mexico;Canada;Argentina;Brazil;Australia;South Africa;Germany
13EUCTR2009-010918-30-IE
(EUCTR)
11/08/200911/03/2009Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism.Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism. 20 patients with hypopituitarism including growth hormone deficiency will be evaluated both on growth hormone replacement and when they have been off it for a 2 month period. They will have been prescribed growth hormone replacement in the form of Genotropin/Genotropin Miniquick/Norditropin prior to inclusion in this study as part of their routine clinical care.
MedDRA version: 9.1;Level: LLT;Classification code 10021067;Term: Hypopituitarism
MedDRA version: 9.1;Classification code 10033662;Term: Panhypopituitarism
MedDRA version: 9.1;Classification code 10056438;Term: Growth hormone deficiency
MedDRA version: 9.1;Classification code 10011318;Term: Craniopharyngioma
MedDRA version: 9.1;Classification code 10036832;Term: Prolactinoma
MedDRA version: 9.1;Classification code 10011651;Term: Cushing's disease
MedDRA version: 9.1;Classification code 10035104;Term: Pituitary tumour
MedDRA version: 9.1;Classification code 10061538;Term: Pituitary tumour benign
Trade Name: Genotropin 5.3mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin 12mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 0.2mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 0.4mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 0.6mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 0.8mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 1.0mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 1.2mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniqu
Amar Agha, Beaumont HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Ireland
14NCT00939523
(ClinicalTrials.gov)
July 200914/7/2009Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard TherapyTargeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard TherapyPituitary Adenomas;ProlactinomasDrug: LapatinibCedars-Sinai Medical CenterNULLCompleted18 YearsN/AAll9Phase 2United States
15EUCTR2008-007348-32-FR
(EUCTR)
06/05/200905/06/2009An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NAAn open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NA The following tumors are included:1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)3. Ectopic ACTH-secreting (EAS) tumors4. Nelson’s syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10062476;Term: Neuroendocrine tumor
Product Name: pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Product Name: pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Product Name: pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
100Phase 2France;Spain;Germany;Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2006-007036-95-DE
(EUCTR)
02/07/200823/01/2009Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept studyMonocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study Prolactinoma
MedDRA version: 9.1;Level: LLT;Classification code 10036832;Term: Prolactinoma
Product Code: SOM230
INN or Proposed INN: Pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für EndokrinologieNULLNot RecruitingFemale: yes
Male: yes
Germany
17NCT00460616
(ClinicalTrials.gov)
January 200713/4/2007Cardiac Valve Complications in Prolactinomas Treated With CabergolineObservational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With CabergolineProlactinomasDrug: CabergolineFederico II UniversityNULLCompleted18 Years65 YearsBoth50Italy
18NCT00697814
(ClinicalTrials.gov)
June 200412/6/2008Clomiphene in Males With Prolactinomas and Persistent HypogonadismRecovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent HypogonadismHypogonadotropic Hypogonadism;ProlactinomaDrug: Clomiphene citrateFederal University of São PauloNULLCompleted18 Years70 YearsMale15Phase 2Brazil